Among HIV/HCV-coinfected patients in Canada with documented cirrhosis, 36% did not receive guideline-recommended screening ultrasounds.
Liver disease, including hepatocellular carcinoma, is an important cause of morbidity and mortality among patients with HIV/hepatitis C virus (HCV) coinfection. Surveillance for hepatocellular carcinoma in such individuals could improve outcomes; both the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver recommend ultrasound screening for HIV/HCV-coinfected patients with cirrhosis (every 6–12 months and every 6 months, respectively).
To examine compliance with these recommendations, investigators in Canada studied a cohort of HIV/HCV-coinfected patients. Among the 952 patients with >6 months of follow-up between March 2003 and October 2012, 144 had documented cirrhosis and 220 had po…
Reviewing Author
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)
DisclosuresGrant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; NIH/National Institute on Drug Abuse
Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes; Vaccines
Leadership Positions in Professional SocietiesInternational Antiviral Society–USA (Board of Directors); Infectious Diseases Society of America (Past President)